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Human herpesvirus 8 (HHV-8) or Kaposi’s sarcoma associated herpesvirus (KSHV) is associated with Kaposi’s sarcoma
and primary effusion lymphoma. In vivo, HHV-8 DNA and transcripts have been detected in B cells, endothelial cells,
macrophages, and epithelial cells. HHV-8 infects a variety of cell lines of human and animal origin, leading to latent or
abortive infection. This study shows that the broad cellular tropism of HHV-8 may be in part due to its interaction with the
ubiquitous host cell surface molecule, heparan sulfate (HS). This conclusion is based on the following findings: (i) HHV-8
infection of human foreskin fibroblast (HFF) cells was inhibited in a dose-dependent manner by soluble heparin, a
glycosaminoglycan closely related to HS. Chondroitin sulfates A and C did not inhibit HHV-8 infection. (ii) Enzymatic removal
of HFF cell surface HS with heparinase I and III reduced HHV-8 infection. (iii) Soluble heparin inhibited the binding of
radiolabeled HHV-8 to human B cell lines, embryonic kidney epithelial (293) cells, and HFF cells, suggesting interference at
the virus attachment stage. (iv) Cell surface adsorbed HHV-8 was displaced by soluble heparin. (v) Radiolabeled HHV-8 also
bound to wild-type HS expressing Chinese hamster ovary (CHO-K1) cells. In contrast, binding of virus to mutant CHO cells
deficient in HS was significantly reduced. These data show that the g2 herpesvirus HHV-8, similar to some members of a,
b, and g2 herpesviruses, adsorbs to cells by binding to cell surface HS-like moieties. Heparin did not completely prevent the
binding and infectivity of HHV-8, suggesting that HHV-8 interactions with HS could be the first set of ligand–receptor
interaction leading to the binding with one or more host cell receptors essential for the subsequent viral entry process.
© 2001 Academic Press
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1INTRODUCTION
Human herpesvirus 8 (HHV-8) or Kaposi’s sarcoma
associated herpesvirus (KSHV) DNA has been detected
in the Kaposi’s sarcoma (KS) tissues from all epidemio-
logic forms of KS (Boshoff et al., 1995; Chang et al., 1994;
Dubin et al., 1999; Schulz et al., 1998). HHV-8 DNA has
been also detected in body-cavity-based B-cell lympho-
mas (BCBL) and in the B cells of HIV-positive and HIV-
negative individuals (Dubin et al., 1999; Schulz et al.,
1998). HHV-8 encodes for more than 80 ORFs. The des-
ignation of ORFs 1 to 75 is based on the similarity to
herpesvirus saimiri (HVS) ORFs and the unique ORFs
designated with the prefix K (Russo et al., 1996; Neipel et
al., 1997). HHV-8 has counterparts to other herpesvirus
glycoproteins such as glycoproteins gB (ORF 8), gH (ORF
22), gM (ORF 39), and gL (ORF47). In addition to these
conserved glycoproteins, K1 and K8.1 genes encode for
glycoproteins unique for HHV-8 (Russo et al., 1996;
Neipel et al., 1997; Chandran et al., 1998).
In vivo, HHV-8 DNA and transcripts have been identi-
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245fied in human B cells (Schulz et al., 1998), macrophages
(Blasig et al., 1997), endothelial cells (Boshoff et al., 1995;
Schulz et al., 1998), and epithelial cells (Diamond et al.,
1998). HHV-8 has also been shown to infect a variety of
cell types in vitro including human B, endothelial, epithe-
lial, and fibroblast cells as well as owl monkey kidney
and baby hamster kidney fibroblast cells (Blackbourn et
al., 2000; Flore et al., 1998; Moses et al., 1999; Renne et
al., 1998; Vieira et al., 2001). However, a sustained pro-
ductive HHV-8 infection has not yet been established
and inoculation of these cells usually results in an abor-
tive and/or latent infection (Blackbourn et al., 2000; Flore
et al., 1998; Moses et al., 1999; Renne et al., 1998; Vieira
et al., 2001).
The initial virus-cell interaction by some members of a
herpesviruses [herpes simplex virus type1 (HSV-1); her-
pes simplex virus type 2 (HSV-2); pseudorabies virus
(PRV); bovine herpesvirus type 1 (BHV-1)], b herpesvi-
ruses [human cytomegalovirus (HCMV); human herpes-
virus 7 (HHV-7) and g2 herpesvirus [bovine herpesvirus-4
BHV-4)] herpesviruses involves the binding to the ubiq-
itous cell surface proteoglycan heparan sulfate (HS)
Compton et al.,1993; Liang et al., 1993; Mettenleiter et
l., 1990; Neyts et al., 1992; Spear, 1993; Secchiero et al.,
997; Skrincosky et al., 2000; Vanderplasschen et al.,
993; WuDunn and Spear, 1989). We hypothesized that
HV-8’s broad cellular tropism may be in part due to
0042-6822/01 $35.00
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246 AKULA ET AL.interactions with one or more ubiquitous host cell sur-
face molecules such as HS. This hypothesis was tested
by examining the role of HS in the entry of HHV-8.
Incubation of HHV-8 with soluble heparin, a glycos-
aminoglycan (GAG) closely related to HS or the removal
of cell surface HS by heparinase I and III, reduced HHV-8
infection. Heparin blocked the binding of [3H]-thymidine-
abeled HHV-8 to human B, epithelial, and fibroblast
ells. HHV-8 binding was also detected with the HS
xpressing Chinese hamster ovary (CHO-K1) cells while
nly a low percentage of virus bound to CHO mutant
ells deficient in HS. These data suggest that HHV-8
nfection of target cells involves interaction with cell
urface HS molecules.
RESULTS
eparin prevents HHV-8 infection of HFF cells
FIG. 1. Infection of HFF cells with recombinant HHV-8 expressing
uninduced BCBL-1 cells harboring recombinant HHV-8 with GFP-DNA
GFP-BCBL-1 cells have been described elsewhere (Vieira et al., 2001
concentrated and served as the source of GFP-HHV-8 in the infection as
(magnification: 403). (C) Expression of HHV-8 latency associated nucl
5 days postinfection with GFP-HHV-8. The punctate nuclear fluorescenc
rabbit anti-ORF 73 antibodies and anti-rabbit FITC antibodies (magnific
cells (magnification: 1603).Although HHV-8 has a broad in vivo cellular tropism,
analysis of in vitro HHV-8 interaction with host cells andquantitation of infection has been hampered by the ab-
sence of a lytic replication cycle and a reliable plaque
assay. In addition, infection is often abortive and only a
low percentage of HHV-8 infected cells such as human
endothelial and human foreskin fibroblast (HFF) cells
retained the viral genome in a latent form (Blackbourn et
al., 2000; Flore et al., 1998; Moses et al., 1999; Renne et
al., 1998; Vieira et al., 2001). To monitor the HHV-8 bind-
ing and entry process, BCBL-1 cells carrying a recombi-
nant HHV-8 expressing the green fluorescent protein
(GFP-HHV-8) was established (Vieira et al., 2001). Stable
GFP-BCBL-1 cells containing the recombinant DNA was
easily monitored by fluorescence microscopy for the
expression of GFP (Fig. 1A). GFP-HHV-8 in the superna-
tant of TPA induced BCBL-GFP cells was concentrated
and used as the inoculum for infection.
GFP-HHV-8 titer was estimated using HFF cell mono-
layers since infection in these cells can be readily mon-
fluorescent protein. (A) Expression of green fluorescent protein in
fication: 1603). The construction GFP-HHV-8 and the establishment of
s from culture supernatant from TPA-induced GFP-BCBL-1 cells was
B) Expression of GFP in HFF cells 3 days postinfection with GFP-HHV-8
igen (LANA-1) ORF 73 protein in the nuclei of acetone-fixed HFF cells
ating ORF 73 protein (LANA-1) expression was detected by polyclonal
603). (D) Nonreactivity of anti-ORF 73 antibodies with uninfected HFFgreen
(magni
). Viru
says. (
ear ant
e indicitored compared to suspension cultures of human B cells
(Vieira et al., 2001). Three days postinfection, GFP ex-
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247HHV-8 (KSHV) BINDS TO HEPARAN SULFATEpressing cells in eight-well chamber slides were ob-
served by fluorescence microscopy and enumerated
(Fig. 1B). Infection with 50 ml of GFP-HHV-8 stock virus
esulted in approximately 250–280 of green fluorescent
rotein expressing cells per well. Similar to our earlier
bservation (Vieira et al., 2001), infected HFF cells
howed no cytopathic effect, and no lytic cycle associ-
ted protein expressions or infectious virus could be
etected (data not shown). Only a latent infection was
bserved in the HFF cells as evidenced by the presence
f circular HHV-8 representing latent DNA and by the
xpression of HHV-8 latency-associated nuclear antigen
LANA-1) encoded by ORF 73 gene (Vieira et al., 2001).
he earliest time point of LANA-1 detection by IFA was
fter 72 h. Even though the expression of GFP under the
ontrol of promiscuous elongation factor-1-a-promoter
was evident 1 day postinfection, the green fluorescence
signals was weaker and difficult to quantitate. However,
the intensity of fluorescence signals increased over time
and were clearly evident after 3 days postinfection.
Hence GFP-HHV-8 infection was assessed on day 3
postinfection. Since only a latent infection was observed
in the HFF cells, the GFP expressing cells represent
infection by the input virus and not due to reinfection by
the spread of replicating viruses from the infected cells.
We have previously shown that all HFF cells infected
with GFP-HHV-8 expressed LANA-1 (Vieira et al., 2001).
After observing the slides for GFP expressions, cells
were fixed with cold acetone and tested with polyclonal
rabbit antibodies against LANA-1. Acetone fixation
quenched the signals from GFP considerably and hence
the punctate nuclear fluorescence representing LANA-1
was easily detected in the GFP expressing cells (Fig.
1C). This confirmed that the expression of GFP serves as
an indicator of HHV-8 entry and infection. Specificity of
GFP-HHV-8 entry and infection was also verified by neu-
tralization assays using sera from HIV1KS1 individuals
and monoclonal and polyclonal antibodies against
HHV-8 envelope glycoproteins (manuscript in prepara-
tion).
Heparin is closely related to HS and inhibition of virus
infectivity by heparin treatment has been considered as
an evidence for members of a, b, and g2 herpesviruses
nteraction with cell surface HS molecules (Compton et
l.,1993; Liang et al., 1993; Mettenleiter et al., 1990; Neyts
t al., 1992; Secchiero et al., 1997; Skrincosky et al., 2000;
pear, 1993; Vanderplasschen et al., 1993; WuDunn and
pear, 1989). To determine whether HHV-8 interaction
ith target cells involves HS, the ability of soluble hep-
rin to prevent GFP-HHV-8 infectivity was examined. A
onstant volume (50 ml) of GFP-HHV-8 was incubated
with different concentrations of heparin or chondroitin
sulfates A and C for 90 min at 37°C and the mixtures
were added to HFF cell monolayers. After incubation at
37°C for 2 h, cells were washed to remove unbound
virus, heparin, and chondroitin sulfates, and incubated
l
lfurther for 3 days at 37°C. HHV-8 infection was assessed
by counting the number of green fluorescent cells. Via-
bility of the cells were not affected by heparin or chon-
droitin sulfates at the concentrations used (data not
shown). Heparin inhibited GFP-HHV-8 infection in a
dose-dependent manner with the inhibition ranging from
65 to 92% and reaching a plateau between 50 and 100
mg/ml of heparin (Table 1). Chondroitin sulfates A and C
did not inhibit GFP-HHV-8 infection even at a concentra-
tion of 1000 mg/ml. Similar results were also seen with
93 cells (data not shown). Since only a latent infection
as observed in the HFF cells without the expression of
ytic cycle proteins and infectious virus, inhibition of GFP
xpression suggested that heparin blocked the infection
f input HHV-8 possibly by inhibiting the interaction of
HV-8 with cell surface HS-like molecules. The inability
f heparin to completely prevent the infectivity of HHV-8
uggests that HHV-8 interaction with HS is probably the
irst set of ligand–receptor interaction leading to the
inding with other host cell receptors essential for the
ubsequent viral entry process.
emoval of HFF cell HS by heparinase I and III
owered HHV-8 infection
Heparinase I and III cleave HS at different sites and
TABLE 1
Heparin Treatment Prevents GFP-HHV-8 Infection of HFF Cells
Heparin
concentration
(mg/ml)a
Number of GFP-HHV-8
infected green
fluorescent cellsb
% Positive cells for
GFP-HHV-8
infectionc
0 244 100
10 234 96 6 8
50 76 31 6 5
100 25 10 6 2
500 24 10 6 2
1000 19 8 6 3
a 50 ml of GFP-HHV-8 was incubated at 37°C for 90 min with DMEM
lone or DMEM containing different concentrations of soluble heparin
r chondroitin sulfate A or C (10, 50, 100, 500, and 1000 mg/ml). This
mixture was added to HFF cell monolayers in 8-well chamber slides
and incubated for 2 h at 37°C. Cells were washed 3 times to remove
virus, heparin, and chondroitin sulfates, and incubated with growth
medium at 37°C. After 3 days, slides were examined by an inverted
fluorescent microscope. Heparin or chondroitin sulfates did not affect
the viability of the cells at the concentrations used.
b Green fluorescent cells (Fig. 1B) indicative of GFP-HHV-8 entry
were counted. After infection with 50 ml of HHV8-GFP stock virus,
pproximately 250–280 green fluorescent-expressing HFF cells per
ell were detected. The average number of GFP-HHV-8 infected green
luorescent cells from three experiments are shown.
c Data presented represent the average 6 SD of three experiments.
Chondroitin sulfate A and C did not inhibit GFP-HHV-8 infection even at
a concentration of 1000 mg/ml.iberate them from the cell surface (Stringer and Gal-
agher, 1997). Removal of cell surface HS-like molecules
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248 AKULA ET AL.by heparinase I and III has been shown to reduce the
infection of herpesvisuses (Shukla et al., 1999; Vander-
plasschen et al., 1993). To confirm the role of HS in
HHV-8’s interaction with cell surface HS-like molecules,
HFF cells were first treated for 2 h with a mixture of
heparinase I and III and the ability of GFP-HHV-8 to infect
these cells were assessed. Heparinase I and III at the
concentrations used did not show any detectable toxicity
on HFF cells and the viability of the cells was not af-
fected. GFP-HHV-8 infectivity was reduced by pretreating
HFF cells with heparinase I and III (Table 2). Maximum
inhibition (68%) was seen with 4 unit/ml of heparinase I
and III and the higher concentrations did not result in
increased inhibition. The inability of heparinase I and III
treatment to completely prevent the virus infection may
be in part due to the lower efficiency of this method and
also possibly due to binding of HHV-8 to other host cell
surface molecules in the absence of HS. Nevertheless,
these results also suggest an interaction between HHV-8
and cell surface HS-like molecules.
Heparin blocks HHV-8 binding to the host cells
In the infectious process of some members of a, b,
and g2 herpesviruses, HS has been shown to be in-
olved in the attachment stage of infection (Compton et
l.,1993; Liang et al., 1993; Mettenleiter et al., 1990; Neyts
t al., 1992; Spear, 1993; Secchiero et al., 1997; Skrin-
osky et al., 2000; Vanderplasschen et al., 1993; WuDunn
nd Spear, 1989). To determine whether HS is involved in
TABLE 2
Enzymatic Removal of HS with Heparinase I and III Lowers
GFP-HHV-8 Infection of HFF Cells
Heparinase I and III
concentration
(units/ml)a
Number of GFP-HHV-
8-infected green
fluorescent cellsb
% Positive cells for
GFP-HHV-8
infectionc
0 251 100
1 133 53 6 8
2 124 49 6 5
4 81 32 6 1
6 96 38 6 1
8 96 38 6 5
10 92 37 6 4
a Confluent monolayers of HFF cells in chamber slides were overlaid
ith different concentrations of heparinase I and III or PBS alone and
ncubated at 37°C for 2 h. The cells were washed and incubated with
FP-HHV-8 at 37°C. After 2-h incubation, cells were washed and
ncubated with growth medium at 37°C. At 3 days, green fluorescent
ells, indicative of HHV-8 entry, were counted by an fluorescence
icroscope. Heparinase I and III at the concentrations used did not
ffect the viability of the cells.
b The average number of GFP-HHV-8-infected green fluorescent cells
from three experiments are shown.
c Data presented represent the average 6 SD of three experiments.he initial stage of HHV-8 absorption to the host cells, we
xamined the ability of heparin to block the binding of3H]-thymidine-labeled HHV-8 to the cells. HHV-8 binding
o cells was initially examined by electron microscopy
E17). [3H]-thymidine-labeled virus was allowed to bind
he untreated and paraformaldehyde-treated BJAB cells
HHV-8 negative B cells) at 37°C for 15 min, washed, and
ixed with 2% glutaraldehyde. Thin sections were pre-
ared and examined by transmission electron micros-
opy. After a 15-min incubation, herpesvirus particles
ound to the surfaces of paraformaldehyde-treated (Figs.
A and 2B) and untreated (Figs. 2C, 2D, and 2E) cells
ere observed. Only enveloped virus particles were
een in these EM examinations indicating the specificity
f labeled virus binding. We did not observe virus entry
ith paraformaldehyde-treated BJAB cells. In contrast,
ntry of virus was observed in unfixed BJAB cells (Figs.
C–2F). Several virus particles in the process of binding
nd entering the cells via the endocytic vesicles were
bserved (Figs. 2C–2F).
To quantitate HHV-8 binding to its target cells, different
oncentrations (cpm) of purified [3H]-thymidine-labeled
HV-8 were added to BJAB, BCBL-1, 293, and HFF cells
nd incubated at 37 or 4°C for 1 h. Cells were washed,
recipitated with TCA, and measured for the cell asso-
iated radioactivity. We used the 0.1% paraformaldehyde-
reated cells, since this treatment allows the binding of
irus but prevents the entry into cells and thus allows the
erformance of binding assays at 37°C (Miller and Hutt-
letcher, 1988). Labeled HHV-8 bound to BCBL-1, BJAB,
93, and HFF cells in a dose-dependent manner (Fig.
A). The maximum binding was observed with BCBL-1
ells which may be due the high concentration of HHV-8
eceptors and/or high affinity receptors (Fig. 3A). Similar
esults were also observed when HHV-8 binding assays
ere performed at 4°C with unfixed cells (data not
hown). Dose-dependent HHV-8 binding was also de-
ected with Raji, HeLa, Vero, BHK-21, and mouse L cells
data not shown).
To determine whether heparin inhibits HHV-8 binding,
constant quantity of purified labeled virus within the
inear range of the dose-response curve (Fig. 3A) was
ixed with medium alone or with different concentra-
ions of heparin and incubated at 37°C for 1 h. These
ere then added to the paraformaldehyde-treated target
ells, incubated at 37°C for 1 h, washed 5 times, precip-
tated with TCA, and counted. The cell-bound virus cpm
n the presence or absence of heparin and the percent-
ge inhibition of virus binding were calculated. Soluble
eparin significantly inhibited the binding of labeled
HV-8 to all cell lines tested in a dose-dependent man-
er (Fig. 3B). The percentage inhibition plateaued be-
ween 10 and 100 mg/ml of heparin for all cell lines and
the maximum inhibition ranged from 75 to 93%. Similar
results were also observed when heparin treatment and
binding assays were performed at 4°C with unfixed cells
(data not shown). Specificity was shown by the absence
of inhibition by chondroitin sulfates A and C even at a
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249HHV-8 (KSHV) BINDS TO HEPARAN SULFATEconcentration of 1000 mg/ml (data not shown). Binding of
3H]-thymidine-labeled g1 Epstein–Barr virus (EBV) to
JAB or Raji cells were not blocked by similar concen-
rations of heparin (data not shown). The inhibition of
HV-8 binding to target cells by heparin suggested that
HV-8 interacts with cell surface HS at the stage of
bsorption. The inability of heparin to completely prevent
he virus binding suggests that HHV-8 must be also
inding to other host cell molecules.
isplacement of cell surface adsorbed HHV-8 by
eparin
To determine the specificity of HHV-8 interaction with
ell surface HS and the inhibition by heparin, labeled
irus was first allowed to adsorb to the paraformalde-
yde-fixed HFF cells and at different times postabsorp-
ion, heparin was added to a final concentration of 10
mg/ml. Cells were further incubated for a total period of
60 min at 37°C and the cell-associated radioactivity
counted. Pretreatment of HFF cells with heparin did not
affect HHV-8 binding and bound virus was not eluted
FIG. 2. Electron micrographs of BJAB cells infected with HHV-8. [3H]-
nd unfixed BJAB cells at 37°C, washed after 15 min, and fixed with
icroscopy. (A and B) Enveloped virus particles bound to the paraforma
: 64,0003. B: 82,0003. (C to F) Enveloped virus particles in the pro
nveloped virus particles in the process of endocytosis and within thewith washes without heparin (data not shown). In con-
trast, when heparin was added to the virus–cell mixture, Rit was capable of displacing already adsorbed virus even
when added 40 min after virus addition to the cells (Fig.
3C). Specificity was shown by the absence of HHV-8
displacement by chondroitin sulfates even at a concen-
tration of 1000 mg/ml (data not shown). Reversal of
HHV-8 binding to the cells by heparin not only demon-
strated the specificity of HS interaction with HHV-8, but
also confirmed that these interactions occur at an early
stage of HHV-8 absorption to the host cells. The partial
reversal of binding by the addition of heparin after 50 min
of virus–cell interaction (Fig. 3C) suggested the possible
onset of interactions between viral envelope glycopro-
teins and cellular receptors other than HS molecules.
HHV-8 binds to HS expressing CHO-K1 cell line but
not to cells lacking HS
To verify the role of HS in the attachment of HHV-8 to
the target cells, binding assays were done with wild-type
CHO-K1 cell line expressing HS and its two mutant cell
lines, pgsD-677 cells (deficient in HS but not chondroitin
sulfate) and pgsA-745 cells (deficient in both HS and
ne-labeled HHV-8 was allowed to bind 0.1% paraformaldehyde-treated
taraldehyde. Thin sections were examined by transmission electron
-treated BJAB cell surfaces are indicated by the arrows. Magnification:
f binding and entry into the unfixed BJAB cells. Arrows indicate the
ytic vesicles. Magnification: C: 56,0003; D, E, and F: 64,0003.thymidi
2% glu
ldehydechondroitin sulfate) (Esko et al., 1985; Lidholt et al., 1992).
adiolabeled HHV-8 bound readily to the CHO-K1 cells to
250 AKULA ET AL.
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251HHV-8 (KSHV) BINDS TO HEPARAN SULFATEthe same extent as HFF and BJAB cells (Fig. 4). In
contrast, binding to the mutant cells was significantly
impaired with only about 10% of HHV-8 binding to the
pgsD-677 and pgsA-745 cells (Fig. 4). These results con-
firmed the interaction of HHV-8 with the cell surface HS.
The low percentage of HHV-8 binding to the cells lacking
HS further supported the notion that HHV-8 also binds
other host cell molecules.
DISCUSSION
Animal cell membranes are abundant with proteogly-
cans, which are made of a protein core with one or more
covalently attached GAG chains that bind several differ-
ent protein ligands (Kjellen and Lindhl, 1991; Rostand
and Esko, 1997). HS and other GAGs are present on the
proteoglycans and expressed as integral membrane pro-
FIG. 4. Binding of [3H]-thymidine-labeled HHV-8 to CHO cell lines.
lacking HS but not chondroitin sulfate) and pgsA-745 (lacking both
ncubated with different concentrations of purified [3H]-thymidine-label
nd counted. Each reaction was done in triplicate and each point rep
FIG. 3. Binding of [3H]-thymidine-labeled HHV-8 to the target cells
araformaldehyde-fixed HFF, 293, BJAB, and BCBL-1 cells. Various conc
ere incubated with the paraformaldehyde-treated cells at 37°C fo
ell-associated radioactivity determined. Each reaction was done in trip
nhibition of [3H]-thymidine-labeled HHV-8 binding to the target cells by
reparation was mixed with medium alone or with different concentrat
dded to the paraformaldehyde-treated target cells, incubated at 3
ell-associated virus cpm in the presence or absence of heparin and
eparin, approximately 29, 11, 15, and 18% of the input radioactivity bec
eaction was done in triplicate and each point represents the average 6
ell surface by heparin. HFF cell monolayers treated with paraformald
imes, monolayers were incubated with medium (controls) or with me
eriod of 60 min at 37°C, washed 5 times, precipitated with TCA, and c
nd the percentage inhibition of virus binding were calculated. Each reaction
hree experiments. In the absence of heparin, approximately 18% of the inputteins, glycerol phosphatidyl inositol-linked membrane
proteins, and proteins of extracellular matrices (Rostand
and Esko, 1997; Stringer and Gallagher, 1997). This an-
atomical feature of the cell membrane is exploited by
viruses in their entry process. Interaction with HS as an
initial step in the virus binding to the host cells was first
described for the a-herpesvirus, HSV-1 (Spear, 1993).
ince then, PRV (a-herpesvirus), BHV-1 (a-herpesvirus),
CMV (b-herpesvirus), HHV-7 (b-herpesvirus), and
BHV-4 (g2-herpesvirus) have all been shown to interact
pecifically with cell surface HS (Compton et al.,1993;
iang et al., 1993; Mettenleiter et al., 1990; Neyts et al.,
992; Spear, 1993; Secchiero et al., 1997; Skrincosky et
al., 2000; Vanderplasschen et al., 1993; WuDunn and
Spear, 1989). Viruses from other families, such as human
immunodeficiency virus type 1 (HIV-1) (Roderiquez et al.,
yers of wild-type CHO-K1 cells and of two CHO mutants, pgsD-677
d chondroitin sulfate) were treated with 0.1% paraformaldehyde and
-8 at 37°C for 1 h. Cells were washed 5 times, precipitated with TCA,
the average 6 SD of three experiments.
nhibition by soluble heparin. (A) Dose-dependent HHV-8 binding to
ons of purified [3H]-thymidine-labeled HHV-8 (2 3103 to 2.4 3 104 cpm)
Cells were washed extensively and precipitated with TCA and the
and each point represents the average 6 SD of three experiments. (B)
e heparin. A constant quantity of purified labeled virus (1.2 3 104 cpm)
heparin and incubated at 37°C for 1 h. These preparations were then
r 1 h, washed 5 times, precipitated with TCA, and counted. The
centage inhibition of virus binding were calculated. In the absence of
sociated with the BCBL-1, BJAB, HFF, and 293 cells, respectively. Each
three experiments. (C) Displacement of adsorbed HHV-8 from the HFF
were incubated with labeled HHV-8 (1.2 3 104 cpm). At the indicated
ontaining heparin (10 mg/ml). Cells were further incubated for a total
. The cell-associated virus cpm in the presence or absence of heparinMonola
HS anand i
entrati
r 1 h.
licate
solubl
ions of
7°C fo
the per
ame as
SD of
ehyde
dium c
ountedwas done in triplicate and each point represents the average 6 SD of
radioactivity became associated with the HFF cells.
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252 AKULA ET AL.1995), vaccinia virus (Chung et al., 1998), Sindbis virus
(Byrnes and Griffin, 1998), Dengue virus (Chen et al.,
1997), foot and mouth disease virus (Jackson et al., 1996),
respiratory syncytial virus (Feldman et al., 2000; Krusat
and Streckert, 1997), and adeno-associated virus (Sum-
merford and Samulski, 1998) also bind the HS during
their multistep virus entry process.
The g2-herpesvirus HHV-8 has a broad cellular tro-
ism (Blackbourn et al., 2000; Blasig et al., 1997; Boshoff
t al., 1995; Diamond et al., 1998; Dubin et al., 1999; Flore
t al., 1998; Moses et al., 1999; Renne et al., 1998; Schulz
t al., 1998; Vieira et al., 2001). HHV-8 binds to a variety
f cells and binding leads to entry in most of the cells as
hown by the detection of HHV-8 DNA, limited HHV-8
ene expression and green fluorescent protein expres-
ion in human B cells, 293 cells, human endothelial cells,
FF cells, owl monkey kidney cells, BHK-21 cells, human
ladder carcinoma, prostate carcinoma, lung carcinoma,
nd squamous carcinoma cells (Blackbourn et al., 2000;
lore et al., 1998; Moses et al., 1999; Renne et al., 1998;
ieira et al., 2001). This broad tropism could be in part
xplained by the ability of HHV-8 to bind the ubiquitous
ell surface HS molecule.
Our studies suggested that HS mediated binding of
HV-8 occur at an early stage of virus–cell interaction
nd is a reversible process. This resembles the se-
uence of events demonstrated for other herpesviruses,
n which the interaction with cell surface HS is required
o concentrate the virions on the cell surfaces and thus
acilitating the virus binding to other cell surface recep-
ors (Haywood, 1994; Spear, 1993). The inhibition of
HV-8 binding to target cells by heparin suggested that
HV-8 interacts with cell surface HS at the stage of
bsorption. The inability of heparin to completely prevent
he virus binding and infectivity of HHV-8 suggests that
HV-8 interactions with HS is probably the first set of
igand–receptor interactions leading to the binding with
ther host cell receptors essential for the subsequent
iral entry process. These putative second receptors for
HV-8 interactions need to be identified.
Heparin at a concentration of 10 mg/ml of heparin
lowered the binding of [3H]-thymidine-labeled HHV-8 to
ost cells by 80%. However, at least fivefold more con-
entration of heparin was needed to lower the HFF cells’
nfection of GFP-HHV-8 to the same extent and this may
eflect the difference in the experimental systems used.
ince the GFP-HHV-8 virus preparation contained both
he wild-type and the recombinant virus (Vieira et al.,
001), infection of cells were due to both population of
iruses. Cell-associated cpm represented the binding of
ll virus populations labeled with [3H]-thymidine, while
GFP expression represented the infection by GFP-HHV-8
only. Hence, additional concentration of heparin required
was probably to prevent the infection of both wild-type
and GFP-HHV-8 population of viruses compared to theconcentration required to inhibit the radiolabeled virus
binding.
Inspection of the structure of heparin/heparan sulfate
and sequence analysis of the heparin binding domain
(HBD) of several proteins suggested that the negatively
charged sulfate or carboxylate groups on heparin could
interact via electrostatic interactions to positively
charged residues in a protein or peptide (Cardin and
Weintraub, 1989). HBDs are enriched with positively
charged basic amino acids (lysine, arginine, and histi-
dine). Two typical HBDs (XBBXBX and XBBBXXBX) have
been predicted, where B is a basic residue and X can be
any other residue, but usually a hydrophobic residue
(Cardin and Weintraub, 1989). Predictive analysis of
HHV-8 sequence revealed the presence of putative HBD
in HHV-8 gB, gH, gM, and gpK8.1A (data not shown). The
role of these glycoproteins in the interaction with HS is
under investigation.
MATERIALS AND METHODS
Cells
HFF and 293 monolayer cells were grown in Dulbec-
co’s modified Eagle’s medium (DMEM; Gibco BRL, Grand
Island, NY) with 2 mM glutamine, 10% fetal bovine serum
(FBS), and antibiotics. CHO-K1 cells (ATCC-CCL-61)
(Esko et al., 1985), HS deficient CHO derivative pgsD-677
cells (ATCC-CRL-2244), HS, and chondroitin sulfate defi-
cient CHO derivative pgsA-745 cells (ATCC-CRL-2242)
(Lidholt et al., 1992) were grown in Ham’s F12K medium
(Gibco BRL) with 10% FBS and antibiotics. Suspension
cultures of BCBL-1 cells (HHV-8 1 human B cells) (Renne
et al., 1996), recombinant green fluorescence protein-
HHV-8 (GFP-HHV-8) harboring BCBL-1 cells (Vieira et al.,
2001), and BJAB cells (HHV-8 negative human B cells)
were grown in RPMI 1640 medium with glutaMAX I
(Gibco BRL) with 10% FBS and antibiotics. BCBL-1 cells
contain about 40 copies of HHV-8 viral genome in a
latent form and about 20% of the cells enter lytic cycle
after induction with 12-O-tetradecanoylphorbol-13-ace-
tate (TPA) (Sigma, St. Louis, MO) (Renne et al., 1996;
Schulz et al., 1998). Supernatant from TPA-induced
BCBL-1 cells serve as the source of virus.
Recombinant HHV-8 expressing green fluorescence
protein
The construction of recombinant HHV-8 expressing
the green fluorescence protein has been described else-
where (Vieira et al., 2001). Briefly, a DNA fragment en-
coding green fluorescent protein (GFP) expressed by the
promiscuous elongation factor-1-a-promoter and the
eomycin-resistant protein (Neor) expressed by the RSV
promoter was inserted into the DraIII site in the 4.8-kb
BamHI HHV-8 fragment (genomic position 83710). This
fragment was electroporated into BCBL-1 cells and
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stablishment of stable cells (GFP-BCBL-1) containing
he recombinant DNA was easily monitored by fluores-
ence microscopy for the expression of GFP (Fig. 1A).
GFP-HHV-8 in the supernatant of TPA-induced BCBL-
FP cells was concentrated as previously described
Vieira et al., 2001) and used as the inoculum for infec-
ion. Briefly, about 1500 ml of BCBL-1 cells grown to a
ensity of 5 3 105/ml were induced with 20 ng/ml of TPA.
On day 6, culture supernatant was centrifuged at 5000 g
to remove the cells and cell debris. The virus was pel-
leted by centrifugation at 25,000 g for 90 min. Pellets
were suspended in 1/250 original volume of medium,
reclarified by centrifugation at 400 g at 4°C for 10 min 4
times, and filtered through 0.45-mm membrane filters
Pall Corporation, Ann Arbor, MI). Aliquots were stored at
70°C.
FP-HHV-8 infection and inhibition by heparin
GFP-HHV-8 (50 ml) was incubated at 37°C for 90 min
with DMEM alone or with DMEM containing different
concentrations of soluble heparin and chondroitin sul-
fates A and C (10, 50, 100, 500, and 1000 mg/ml). This
mixture was added to HFF cell monolayers in eight-well
chamber slides (Nagle Nunc International, Naperville,
IL), incubated for 2 h at 37°C, washed 3 times to remove
unbound virus, heparin, and chondroitin sulfates, and
incubated with growth medium at 37°C. After 3 days,
slides were examined by a Nikon Eclipse TE300 inverted
fluorescent microscope. Green fluorescent cells (Fig. 1B)
indicative of GFP-HHV-8 entry were counted using Nikon
Magna firewire digital imaging system. After infection
with 50ml of HHV8-GFP stock virus, approximately 250–
280 green fluorescent expressing HFF cells per well
were detected.
After fluorescence microscopic observations, media
from these slides were removed and dried, and cells
were fixed with cold acetone for 10 min. Slides were
tested in an indirect immunofluorescence assay with a
polyclonal rabbit antibodies against LANA-1 (Moses et
al., 1999). Briefly, fixed cells were incubated for 30 min at
37°C with prestandardized dilution of rabbit anti-ORF 73
IgG antibodies. After incubation, slides were washed
rigorously in PBS and incubated further for 30 min at
37°C with a prestandardized dilution of fluorescein iso-
thiocyanate (FITC)-conjugated goat anti-rabbit IgG. After
washing, slides were counterstained with 1:10,000 dilu-
tion of Evans blue (Sigma) for 5 min at room temperature,
washed, and mounted with 50% (v/v) glycerol in PBS.
Slides were examined under a fluorescence microscope.
Effect of HS removal by heparinase I and III on GFP-
HHV-8 infectionCell-surface HS removal by heparinase I and III was
done as per methods described preciously (Shukla et eal., 1999; Vanderplasschen et al., 1993). Briefly, conflu-
ent monolayers of HFF cells in chamber slides were
overlaid with different concentrations of heparinase I
and III or PBS alone and incubated at 37°C for 2 h. The
cells were washed and incubated with GFP-HHV-8 at
37°C. After a 2-h incubation, cells were washed and
incubated with growth medium at 37°C. At 3 days,
green fluorescent cells, indicative of HHV-8 entry, were
counted by a fluorescence microscope. Heparinase I
and III at the concentrations used did not have any
detectable toxicity on HFF cells and the viability of the
cells were not affected.
Radiolabeled HHV-8
[3H]-thymidine HHV-8 in the TPA induced BCBL-1 cells
upernatant was concentrated and purified as per pro-
edure described previously (Lake and Hutt-Fletcher,
000). Briefly, about 1500 ml of BCBL-1 cells grown to a
ensity of 5 3 105/ml were induced with TPA and added
ith 2 mCi/ml of [3H]-thymidine (TRK61; specific activity:
851GBq/mmol; Amersham Pharmacia Biotech, Apiscat-
away, NJ). An additional 2 mCi/ml of [3H]-thymidine was
added 2 days later. Briefly, after 6 days post-TPA induc-
tion, culture supernatants were centrifuged at 5000 g at
4°C for 10 min to remove the cells and cell debris. Virus
in the clarified supernatant was pelleted by centrifuga-
tion at 27,000 g at 4°C for 90 min. Pellets were resus-
pended in 1/500 original volume of RPMI 1640, reclarified
by centrifugation at 400 g at 4°C for 10 min 4 times, and
filtered through 0.45-mm filters.
Concentrated virus was purified using Nycodenz
(Sigma) as per the methods well established for the
purification of EBV (Lake and Hutt-Fletcher, 2000). Briefly,
a 24–42% continuous gradient of Nycodenz (Sigma) in 1
mM potassium phosphate was made by layering 1 ml of
42, 40, 38, 36, 34, 32, 30, 28, 26, and 24% Nycodenz in a
centrifuge tube and allowing the steps to diffuse over-
night at 4°C. Then, 500 ml of concentrated virus was
layered on top of the gradient and centrifuged in a
Beckman SW41 Ti rotor at 70,000 g for 2 h at 4°C (Lake
and Hutt-Fletcher, 2000). Fractions (0.5 ml) were col-
lected from the top. The refractive index was measured
with 25-ml aliquots. Aliquots (10 ml) were spotted on
filters, dried, untreated or precipitated with tricholoroace-
tic acid (TCA), and counted. Fractions were dialyzed
against phosphate-buffered saline to remove Nycodenz
and were tested for binding with cells as described
below. Virus collected from the 28–30% interface con-
tained the enveloped viruses and showed the maximum
cell binding activities. Purity of the virus was also mea-
sured by electron microscopy and Western blots with
Mabs against HHV-8 virion envelope associated gpK8.1A
and nonstructural ORF 59 proteins (Chan et al., 1998; Zhu
t al., 1999).
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254 AKULA ET AL.Radiolabeled HHV-8 binding assays
Cells grown at log phase (viability . 90%) were un-
treated or briefly treated with ice-cold 0.1% paraformal-
dehyde (Miller and Hutt-Fletcher, 1988; Lake and Hutt-
Fletcher, 2000) and used for binding assays. Untreated
and paraformaldehyde-fixed cells were washed 3 times
with RPMI 1640 containing 5% FBS. Used for each reac-
tion were 1 3 106 BJAB or BCBL cells. Purified [3H]-
thymidine-labeled HHV-8 was added to the cell pellets,
mixed, and incubated for 1 h at 4°C for unfixed cells or at
7°C for paraformaldehyde-fixed cells. After incubation,
ells were washed 5 times with RPMI 1640 containing 5%
BS, spotted on filters, radioactivity precipitated with
CA, and counted. HFF, 293 cells, CHO-K1 cells, or its
utant derivative cells (pgsD-677 and pgsA-745) in 24-
ell plates were used for binding assays. After incuba-
ion with the virus, cells were washed 5 times, lysed with
% SDS and 1% Triton X-100, radioactivity precipitated
ith TCA, and counted. All experiments were done in
riplicate and repeated 3 times.
nhibition of radiolabeled HHV-8 binding by heparin
A constant quantity of purified [3H]-thymidine-labeled
irus preparation in RPMI 1640 with 5% FBS was mixed
ith different concentrations of soluble heparin (Sigma)
nd incubated at 37°C for 1 h. These mixtures were then
dded to unfixed or 0.1% paraformaldehyde-treated 1 3
06 BJAB cells (per reaction) or to HFF and 293 cells, and
ncubated further at 4 or 37°C for 1 h. Cells were washed
times with RPMI 1640 containing 5% FBS, radioactivity
recipitated with TCA, and counted.
For testing the ability of heparin to displace the bound
HV-8, a constant quantity of labeled virus was added to
.1% paraformaldehyde-fixed HFF cells. At different time
oints, heparin was added to a final concentration of 10
mg/ml. Cells were further incubated for a total period of
60 min at 37°C and processed as above. All experiments
were done in triplicate and repeated 3 times.
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